Israel suspected that vaccine efficacy may be waning in early July. Made a decision to offer a booster dose for high risk people July 30. And to all adults August 29. Early call.
Data mow support that call. Let's look at boosters.
1/
Their early decision gave early data on boosters. The first data came within days. 2/
The complicating factor is vaccine equity and fairness, and the rise of mutant variants in unvaccinated parts of the world. But on the specific scientific question on whether a booster dose is effective, the evidence is very strong that it is. 6/
Which brings us to some interesting recurrent issues. From masks to vaccines various places have made early judgment calls that others later adopted. Many of us have also had different thresholds.
Some of us called for a booster early on for vulnerable populations. 7/
We see these type of early judgment calls ahead of the CDC now by various places: California, Colorado, New Mexico, New York City.
I don't think we should second guess these judgment calls made in the public interest. Data support them. 9/ google.com/amp/s/www.nyti…
The second issue is that it is fascinating to see how data evolves and how decisions are made. Some of the early data that a booster dose may be effective came quite early. In June. 10/
Its good to recognize just as there are risks in an early call, there are also risks in waiting for perfect data. These are also not easy judgment calls. There is a lot of analysis of data, pros and cons. For leaders, it's good to have deep thinkers and experts on the team.
*now
Sorry about the typo!
*fact
Some questions on why the first 2 doses were not enough.
Some thoughts. Durability of immunity is dependent on many factors:
1) antigen dose 2) the way in which the antigen is presented to the immune system 3) host factors: age, comorbidities 4) interval between exposures
New virus, new vaccines. We are constantly learning.
The first 2 doses continue to provide high degree of protection against severe disease. But because even mild breakthroughs can spread infection to vulnerable and unvaccinated populations, we have to try to get all cases down
• • •
Missing some Tweet in this thread? You can try to
force a refresh
If you don't have immunity, the Covid virus poses a clear and present risk. Get immunity the safe way: Vaccines.
1/
If you already had COVID and think you are safe, don't take chances. Immunity is more durable and effective with another exposure to the same antigen. Basic immunology 101. Get your second exposure the safe way: Vaccines.
2/
If are already fully vaccinated, get a booster if it is offered for your age and risk group in your area. It's the safe way to strengthen immunity.
3/
Minnesota now has the highest number of cases per capita in the country. Florida, the lowest. But don't rush to conclusions. Florida paid a price with a high loss of life in its recent wave, the highest since the start of vaccinations. #GetVaccinated
Breakthrough cases are occurring and people who are eligible need to get boosters. But once again, the vaccines are highly effective in preventing serious disease and deaths.
If prescription drug prices are very high and keep rising, if you reduce out of pocket costs for patients, premiums go up; if you reduce premiums, out of pocket costs for patients go up.
That's the truth.
You cannot have a system that relies on the generosity of Pharma to keep prices affordable. They will keep increasing drug prices to meet targets as the law allows them to set the price and prevents Medicare from negotiating.
Lowering out of pocket costs is a band aid.
You cannot give monopoly protection for >10 years and have no way of negotiating either launch prices or price increases. Particularly when the product is life saving.
As I look at these data, and what's going on in Europe, vaccinated younger people after vaccines and most elderly people are very well protected. But some elderly and immunocompromised may not mount a durable immune response after vaccines.
Boosters are therefore important for elderly and immunocompromised people. Early use of monoclonal antibodies are also important and should be used if available.
Medicare Part D covers >3500 prescription drugs. Over 2400 of these are made by only one manufacturer (monopolies).
The prescription drug plan to let Medicare negotiate covers 10 drugs starting 2025. 20 drugs per year after.
Yet Pharma protests. Let's keep things in context.
New drugs are protected for 9 years from time on market from negotiation. Biologics for 12 years. Price increases capped to inflation.
Which means expect Pharma to "front load" prices. That means make the launch price much higher to cover all of this loss of revenue. @DavidP4AD
Out of pocket for seniors capped. Good. Important.
But it also means someone still pays Pharma. That's Medicare. Which is back to us, the public. So it's not like Pharma is losing money that way either.